Cell metabolism · 2025
Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xue Chunling, Zhao Sihan, Zhou Yifan, Chen Ziming, Liu Ji, Deng Shuang, Zeng Lingxing, Zhao Hongzhe, Xu Zilan, Li Mei, He Xiaowei, Liu Shaoqiu, Liu Shuang, Zhang Shaoping, Peng Xinyi, Wu Xiaoyu, Bai Ruihong, Zhuang Lisha, Wu Shaojia, Zhang Jialiang, Lin Dongxin, Huang Xudong, Zheng Jian
Аннотация
Obesity is correlated with the development of multiple cancer types, and obese patients with pancreatic ductal adenocarcinoma (PDAC) show dismal prognosis and resistance to immune checkpoint blockade (ICB) therapy. The molecular mechanism is largely unknown. Here, we show that obese visceral adipose tissues (VATs) can communicate with distant PDAC by delivering extracellular vesicles (EVs) carrying signal molecules. We reveal that PDAC cells can take VAT-EVs into their lysosomes, where EV-delivered cathepsin A (Ctsa) stabilizes the ribonuclease Rnaset2b to produce free pseudouridine. Pseudouridine activates mast cells via increasing reactive oxygen species (ROSs) and decreasing H3K27me3 modification at the gene promoter. Activated mast cells inhibit CD8+ T cell activity, forming an immunosuppressive tumor microenvironment that enhances cancer progression. Animal experiments indicate that Ctsa knockdown effectively enhances ICB efficacy on PDAC. Our study uncovers a VAT-EV CTSA-pseudouridine-mast cell axis connecting obesity and cancer, which holds promise for developing new therapeutic strategies for obesity-related cancers.